267 related articles for article (PubMed ID: 30006062)
21. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
McClendon AK; Osheroff N
Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase IIα inhibitors.
Thapa Magar TB; Hee Seo S; Shrestha A; Kim JA; Kunwar S; Bist G; Kwon Y; Lee ES
Bioorg Chem; 2021 Jun; 111():104884. PubMed ID: 33872925
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent.
Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P
Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361
[TBL] [Abstract][Full Text] [Related]
24. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
25. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
27. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
[TBL] [Abstract][Full Text] [Related]
28. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
[TBL] [Abstract][Full Text] [Related]
29. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
30. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
[TBL] [Abstract][Full Text] [Related]
31. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
32. NEK5 interacts with topoisomerase IIβ and is involved in the DNA damage response induced by etoposide.
Melo-Hanchuk TD; Slepicka PF; Pelegrini AL; Menck CFM; Kobarg J
J Cell Biochem; 2019 Oct; 120(10):16853-16866. PubMed ID: 31090963
[TBL] [Abstract][Full Text] [Related]
33. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Bandele OJ; Osheroff N
Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
[TBL] [Abstract][Full Text] [Related]
34. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
35. Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
Pedatella S; Cerchia C; Manfra M; Cioce A; Bolognese A; Lavecchia A
Eur J Med Chem; 2020 Feb; 187():111960. PubMed ID: 31869654
[TBL] [Abstract][Full Text] [Related]
36. Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors.
Legina MS; Nogueira JJ; Kandioller W; Jakupec MA; González L; Keppler BK
J Biol Inorg Chem; 2020 May; 25(3):451-465. PubMed ID: 32193613
[TBL] [Abstract][Full Text] [Related]
37. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
38. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
39. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
[TBL] [Abstract][Full Text] [Related]
40. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
